Cixutumumab (IGF1R/CD221) Antibody, Monoclonal | 10-299

Cixutumumab (IGF1R/CD221) Antibody, Monoclonal | 10-299 | Gentaur UK, US & Europe Distribution

Host: N/A

Reactivity: N/A

Homology: N/A

Immunogen: Homo sapiens / IGF1R/CD221 [Homo sapiens]

Research Area: Drug Analogues

Tested Application: N/A

Application: N/A

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: >95%

Clonality: Monoclonal

Clone: N/A

Isotype: IgG1-lambda

Conjugate: Unconjugated

Physical State: N/A

Buffer: PBS buffer pH7.5

Concentration: N/A

Storage Condition: Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚C for 1-2 weeks. Store at -20 ˚C for 12 months. Store at -80 ˚C for long term storage.

Alternate Name: IMC-A12, LY3012217

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: Cixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia, Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate. Cixutumumab is a highly specific recombinant human monoclonal antibody with high affinity for the insulin-like growth factor-I receptor (IGF-IR) . IGF-IR is overexpressed in a variety of tumour types.